Want to see JP:4534 full AI Analyst Report?
Top Page
Mochida Pharmaceutical Co., Ltd.
(4534)
Select Model
Select Model
Rating:66Neutral
Price Target:
¥3,316.00
▼(-8.27% Downside)
Action:Downgraded
Date:05/16/26
The score is driven by strong financial resilience from a low-leverage balance sheet and improving earnings, partly offset by materially inconsistent and sometimes negative operating/free cash flow. Technical signals are currently weak (below key moving averages with negative MACD), while valuation is supportive with a moderate P/E and a ~2.34% dividend yield.
Positive Factors
Conservative balance sheet
Mochida's historically near-zero leverage and large equity base provide durable financial flexibility, allowing continued R&D and product commercialization during downturns. Low structural leverage reduces bankruptcy risk and supports strategic optionality over the next several quarters.
Negative Factors
Volatile cash generation
Irregular OCF and FCF undermine the company's ability to self-fund R&D, sustain dividends, or respond to opportunities. Persistent swings tied to working-capital variability reduce predictability of capital allocation and increase reliance on external financing over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Mochida's historically near-zero leverage and large equity base provide durable financial flexibility, allowing continued R&D and product commercialization during downturns. Low structural leverage reduces bankruptcy risk and supports strategic optionality over the next several quarters.
Read all positive factors
Mochida Pharmaceutical Co., Ltd. (4534) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥106.17B
Dividend Yield2.56%
Average Volume (3M)34.37K
Price to Earnings (P/E)14.0
Beta (1Y)0.65
Revenue Growth11.21%
EPS Growth39.02%
CountryJP
Employees1,479
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)222.94
Shares Outstanding36,390,000
10 Day Avg. Volume38,620
30 Day Avg. Volume34,366
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)0.87
Price to Sales (P/S)1.05
P/FCF Ratio-12.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)208.3
Revenue Forecast (FY)¥110.00B
Mochida Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmace...
How the Company Makes Money
Mochida Pharmaceutical generates revenue primarily from the sale of pharmaceuticals, especially prescription drugs, to hospitals, clinics, and pharmacies in Japan. Its earnings are driven by (1) sales of its in-house products marketed under the Mo...
Mochida Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
90
Very Positive
Cash Flow
46
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 116.95B | 105.16B | 102.89B | 103.26B | 110.18B |
| Gross Profit | 56.26B | 53.79B | 52.07B | 55.12B | 59.55B |
| EBITDA | 13.13B | 11.07B | 8.61B | 11.18B | 17.08B |
| Net Income | 7.90B | 5.68B | 4.55B | 6.65B | 10.57B |
Balance Sheet | |||||
| Total Assets | 182.72B | 163.56B | 162.30B | 161.04B | 165.93B |
| Cash, Cash Equivalents and Short-Term Investments | 31.06B | 51.15B | 46.79B | 60.51B | 61.91B |
| Total Debt | 10.00B | 342.00M | 369.00M | 178.00M | 0.00 |
| Total Liabilities | 42.39B | 32.87B | 34.33B | 34.26B | 37.28B |
| Stockholders Equity | 140.33B | 130.69B | 127.97B | 126.78B | 128.65B |
Cash Flow | |||||
| Free Cash Flow | -10.04B | 7.19B | -9.78B | 5.13B | 4.47B |
| Operating Cash Flow | -7.35B | 9.35B | -7.48B | 7.30B | 7.46B |
| Investing Cash Flow | -16.85B | 17.36B | 74.00M | -2.95B | -2.01B |
| Financing Cash Flow | 7.03B | -2.87B | -6.39B | -6.88B | -5.96B |
Mochida Pharmaceutical Co., Ltd. Technical Analysis
Negative
3615.00
Price Trends
3172.50
Negative
3335.67
Negative
3377.75
Negative
Market Momentum
-13.29
Positive
47.60
Neutral
18.53
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4534, the sentiment is Negative. The current price of 3615 is above the 20-day moving average (MA) of 3143.00, above the 50-day MA of 3172.50, and above the 200-day MA of 3377.75, indicating a bearish trend. The MACD of -13.29 indicates Positive momentum. The RSI at 47.60 is Neutral, neither overbought nor oversold. The STOCH value of 18.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4534.
Mochida Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥106.17B | 13.99 | 5.81% | 2.34% | 11.21% | 39.02% | |
58 Neutral | ¥166.86B | 12.11 | 6.37% | 2.60% | 10.35% | 16.60% | |
55 Neutral | ¥164.23B | 18.03 | ― | 2.28% | 6.69% | 6.72% | |
54 Neutral | ¥60.11B | 30.21 | ― | 4.71% | -4.71% | -78.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥136.69B | 67.09 | 1.46% | 4.85% | -18.25% | -84.71% | |
48 Neutral | ¥197.10B | 37.55 | 2.92% | 2.14% | 5.44% | -72.35% |
* Healthcare Sector Average
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,135.00
-21.26
-0.67%
JP:4521
Kaken Pharmaceutical Co
3,825.00
33.44
0.88%
JP:4547
Kissei Pharmaceutical Co
4,010.00
-360.24
-8.24%
JP:4553
Towa Pharmaceutical Co
3,940.00
685.62
21.07%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,074.00
-429.75
-28.58%
JP:4887
SAWAI GROUP HOLDINGS Co., Ltd.
1,624.00
-303.09
-15.73%
Mochida Pharmaceutical Co., Ltd. Corporate Events
Mochida Pharmaceutical Advances Share Buyback Under ¥2 Billion Authorization
Aug 3, 2026
Mochida Pharmaceutical has disclosed progress on its ongoing share repurchase program, acquiring 90,600 of its own common shares on the Tokyo Stock Exchange between July 1 and July 31, 2026, at a total cost of ¥286.4 million via market purcha...
Mochida Pharmaceutical Posts Strong Q1 Earnings and Confirms Full-Year Outlook
Aug 3, 2026
Mochida Pharmaceutical reported robust results for the three months ended June 30, 2026, with net sales rising 19.1% year on year to ¥31.7 billion and profit attributable to owners of parent surging 67.8% to ¥3.18 billion. Earnings per s...
Mochida Advances Share Buyback Under ¥2 Billion Authorization
Jul 1, 2026
Mochida Pharmaceutical has disclosed the latest progress of its share buyback program authorized under Japan’s Companies Act, repurchasing 60,600 common shares for approximately 192.8 million yen via market purchases on the Tokyo Stock Excha...
Mochida Pharmaceutical Reports Initial Progress on Share Buyback Program
Jun 1, 2026
Mochida Pharmaceutical has disclosed the latest progress of its ongoing share repurchase program authorized under Japan’s Companies Act, confirming it bought back 35,300 common shares on the Tokyo Stock Exchange between May 18 and May 31, 20...
Mochida Pharmaceutical Reshapes Executive Lineup to Sharpen Business Focus
May 15, 2026
Mochida Pharmaceutical announced board-level leadership changes effective June 25, 2026, including revised duties for Representative Directors Junichi Sakaki and Motoi Mitsuishi to streamline oversight across research, biomaterials, pharmaceutical...
Mochida Pharmaceutical Lifts Profits and Raises Dividend Outlook for FY2027
May 15, 2026
Mochida Pharmaceutical reported solid growth for the fiscal year ended March 31, 2026, with net sales rising 11.2% to ¥116.95 billion and profit attributable to owners of parent climbing 39.0% to ¥7.90 billion, reflecting improved margin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.